Defense Contractors Secure Billions with FY26 NDAA, PBMs Face Profit Squeeze

While defense contractors celebrate, the healthcare sector is grappling with significant regulatory shifts. The PBM Kickback Prohibition Act (HR7895) directly targets the revenue models of Pharmacy Benefit Managers by eliminating rebates. This bill fundamentally alters the PBM business model, which relies heavily on these payments, leading to a direct reduction in PBM profitability.

This creates a significant headwind for companies heavily invested in the PBM sector.

Integrated healthcare giants like CVS Health ($CVS), Cigna ($CI), Elevance Health ($ELV), and UnitedHealth Group ($UNH) will experience downward pressure on their stock prices as their PBM segments' profitability is directly challenged. Conversely, pharmaceutical manufacturers like Pfizer ($PFE) and Merck ($MRK) may see a slight positive impact as the rebate system is dismantled, potentially leading to higher net drug prices or reduced pricing pressure. Investors in these integrated healthcare companies should closely monitor their PBM segment performance and strategic adjustments.

Adding to the healthcare sector's complexities, two bills signal increased regulatory scrutiny on pharmaceutical companies. The Protecting Americans from Unsafe Drugs Act of 2026 (HR7980) introduces stricter drug safety regulations, increasing compliance costs and liability for pharmaceutical manufacturers. This bill mandates more rigorous testing protocols, enhanced post-market surveillance, and increased penalties for non-compliance.

Companies such as Pfizer ($PFE), Johnson & Johnson ($JNJ), Merck ($MRK), Eli Lilly ($LLY), and Amgen ($AMGN) will see increased costs and potential revenue delays, creating a bearish outlook.

Similarly, the Stop Pills That Kill Act (HR8005) targets pharmaceutical companies producing certain medications, increasing regulatory scrutiny and potential liability. This bill introduces a new layer of uncertainty into their market valuations. While both bills are in early stages, their progression suggests a future of higher operational expenses and potential product restrictions for major pharmaceutical firms.

Historical precedents show that increased regulation negatively impacts pharmaceutical stock performance.

A bullish signal emerged from the agricultural sector with the introduction of HR8165, a bill to amend the Food and Nutrition Act of 2008 to increase the purchase of animal protein for fiscal years 2026 and 2027 to be included in food assistance distributed under the Emergency Food Assistance Act of 1983. This legislation mandates increased government purchases of animal protein for food assistance, directly boosting demand for meat and poultry producers. This creates a direct, positive demand shock for companies like Tyson Foods ($TSN) and Pilgrim's Pride ($PPC), which will experience increased sales and potentially higher profit margins due to guaranteed government procurement.

Cal-Maine Foods ($CALM), Seaboard Corporation ($SEB), and Pilgrim's Pride ($PPC) are also positioned to benefit. This translates to a bullish outlook for these specific companies and the broader meat processing sector, with stock prices likely reflecting this increased demand as the bill progresses through Congress.

Several bills this week point to a more favorable regulatory environment for energy infrastructure and domestic production. A key legislative package (H.Res. 707 as amended by H.Res. 1131) includes H.R. 1047, which requires the Federal Energy Regulatory Commission (FERC) to reform the interconnection queue process, and H.R. 3062, which establishes a more uniform process for authorizing international border-crossing facilities for oil, natural gas, and electricity. These measures will streamline project approvals, reducing timelines and costs for energy companies.

The American Petroleum First Act (HR8021) further reinforces this bullish sentiment for the energy sector.

This bill mandates increased domestic oil and gas production and utilization, directly benefiting U.S. upstream and midstream energy companies. It prioritizes American energy independence, driving demand for domestic resources and infrastructure. Companies involved in exploration, production, refining, and pipeline transportation will see increased activity and revenue.

Exxon Mobil ($XOM), Chevron ($CVX), EOG Resources ($EOG), Phillips 66 ($PSX), Marathon Petroleum ($MPC), Kinder Morgan ($KMI), and Energy Transfer ($ET) are all positioned to benefit from these legislative efforts. Utility companies like NextEra Energy ($NEE), Southern Company ($SO), and Duke Energy ($DUK) will also see reduced project timelines and improved capital efficiency.

A significant opportunity for the real estate and construction sectors comes from HR8171, a bill to direct the Secretary of Housing and Urban Development to establish a demonstration program to develop workforce housing and affordable housing in areas where the workforce is expanding significantly. This bill directly addresses housing shortages in growing economic areas, creating new construction opportunities. This will provide a bullish impact for homebuilders like Lennar ($LEN), D.R.

Horton ($DHI), PulteGroup ($PHM), KB Home ($KBH), and Toll Brothers ($TOL), who will see increased demand for their services and potential for new contracts. Financial institutions, including JPMorgan Chase ($JPM), Wells Fargo ($WFC), and Bank of America ($BAC), will benefit from expanded construction lending and mortgage origination volumes, making this a positive signal for the broader housing market.

Beyond the major themes, several other signals warrant investor attention. The Dental Care for Veterans Act (HR210) expands VA dental care eligibility to all enrolled veterans, creating a significant new revenue stream for dental service providers and equipment manufacturers. Companies like Dentsply Sirona ($XRAY), Henry Schein ($HSIC), and Envista Holdings ($NVST) will experience increased sales, while healthcare insurers like UnitedHealth Group ($UNH) and CVS Health ($CVS) may find opportunities in administering these benefits.

The Regulation A+ Improvement Act of 2026 expands capital formation opportunities for small and medium-sized enterprises by increasing the maximum offering amount under Regulation A+.

This is a bullish signal for companies utilizing or planning to utilize these offerings, making it easier for them to raise significant capital from retail investors. Trump Media & Technology ($DJT), Microvast Holdings ($MVST), AST SpaceMobile ($ASTS), and Rocket Lab USA ($RKLB) are among those that could benefit.

Finally, HR8169, a bill to amend the Export Control Reform Act of 2018 to provide for expedited consideration of proposals for additions to, removals from, or other modifications with respect to entities on the Entity List, introduces a dynamic element to export controls. While neutral in immediate sentiment, it increases regulatory agility for the U.S. government, directly affecting companies reliant on or restricted by U.S. export controls.

Companies like ASML ($ASML), Taiwan Semiconductor Manufacturing Company ($TSM), Super Micro Computer ($SMCI), Nvidia ($NVDA), AMD ($AMD), Intel ($INTC), and Micron Technology ($MU) will face heightened risk or opportunity depending on specific Entity List actions. Investors should monitor these developments closely for potential market shifts.

This week's legislative activity underscores the profound impact of government policy on market dynamics. From securing defense budgets to reshaping healthcare profitability and streamlining energy projects, Congress continues to be a powerful force in shaping investment landscapes. HillSignal remains committed to providing you with timely, actionable intelligence to navigate these complex signals.